Approval · Notice of Compliance 20939 · 2018
AVASTIN: Notice of Compliance 20939
Issued June 6, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20939
- Date
- June 6, 2018
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Avastin, in combination with lomustine is indicated for the treatment of patients with glioblastoma after relapse or disease progression, following prior therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVASTIN | Not yet assigned | — |
Medicinal ingredients
- BEVACIZUMAB 25 MG per ML